If you try one, dont expect to see more than just a shadow of the weight loss (at best) that people experience from a GLP-1 drug
Yri HM, Fagerlund B, Forchhammer HB, Jensen RH
Keywords: glucagon-like peptide-1 receptor agonist, health technology assessment, type 2 diabetes mellitus, drug evaluation Introduction Hospital-based health technology assessment (HB-HTA) refers to the comprehensive and systematic evaluation of relevant health technologies based on the actual needs of hospitals, using the principles and methods of evidence-based medicine and health technology assessment to make rapid decisions about the selection, acquisition, and use of new technologies to improve health equity and is a commonly used policy analysis tool internationally
These plans cover Part D drugs and Part B drugs
After treatment with BN for 3 months, BMI, fasting blood glucose, glycosylated hemoglobin, visceral and subcutaneous fat, silk protein E1, leptin, C-reactive protein (CRP), and tumor necrosis factor decreased significantly
